5 Key Takeaways
-
1
Optigo Biotherapeutics won the People’s Choice Award at Eyecelerator 2025 during the ARVO annual meeting.
-
2
The company focuses on long-acting intravitreal biologics for treating nAMD, DME, and RVO.
-
3
Optigo's bifunctional fusion proteins link anti-VEGF therapeutics to albumin or hyaluronan to extend drug half-life.
-
4
Preclinical data showed modified molecules maintained activity for 6 months, doubling or tripling aflibercept's half-life.
-
5
Optigo aims to reduce injection frequency while ensuring therapeutic benefits and is seeking partnerships for clinical trials.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.